Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

First in a new blog series by Cancer Research UK Oxford Centre on the ongoing work happening across Oxford, for Blood Cancer Awareness Month.

Stem cell © CRUK Assets Hub

Allogenic stem cell transplantation (allo-SCT) is one of the most common, curative forms of cancer immunotherapy. It has been a treatment option for patients with blood cancers (including leukaemia, lymphoma and myeloma) for over 60 years.

In this type of transplant, a patient receives blood stem and immune cells from another healthy person (a donor). Although the initial aim of allo-SCT was to replenish the blood cell producing capacity that patients lose during harsh chemo- and radio-therapy treatment regimes, clinicians and researchers soon realised that donor immune cells specifically destroy the remaining cancer cells through an effect called “graft-vs-tumour”.

This remarkable curative treatment option is a standard treatment, which is routinely used in younger patients with otherwise incurable blood cancers. However, the treatment is associated with significant side effects and can result in 5-25% mortality within the first 100 days of receiving treatment. This toxicity limits wider use of the treatment.

Read the full blog on the Cancer Research UK Oxford Centre website

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.